Table 2.
Univariate and multivariate analysis of risk factors associated with in-hospital death in COVID-19 patients.
| Univariable OR (95% CI) | p value | Multivariable OR (95% CI) | p value | |
|---|---|---|---|---|
| Demographics and clinical characteristics | ||||
| Age, years | 1.121 (1.085–1.158) | <0.0001 | 1.099 (1.057–1.143) | <0.0001 |
| Female sex (vs male) | 0.431 (0.241–0.772) | 0.005 | 0.529 (0.219–1.277) | 0.157 |
| Comorbidity present (vs not present) | ||||
| Hypertension | 0.159 (0.084–0.301) | <0.0001 | ||
| Diabetes | 0.289 (0.129–0.647) | 0.003 | ||
| Cardiovascular disease | 0.153 (0.065–0.363) | <0.0001 | ||
| Respiratory system disease | 0.068 (0.015–0.321) | 0.001 | ||
| Laboratory findings | ||||
| White blood cell count, × 109/L | 1.411 (1.263–1.576) | <0.0001 | ||
| Neutrophil count, × 109/L | 1.595 (1.394–1.825) | <0.0001 | ||
| Lymphocyte count, × 109/L | 0.020 (0.007–0.059) | <0.0001 | ||
| Monocyte count, × 109/L | 0.258 (0.065–1.034) | 0.056 | ||
| Prothrombin time, s | 3.285 (2.186–4.936) | <0.0001 | ||
| Activated partial thromboplastin time, s | 1.146 (1.052–1.249) | 0.002 | ||
| D-dimer, mg/L | 1.347 (1.189–1.525) | <0.0001 | 1.294 (1.138–1.473) | <0.0001 |
| Aspartate aminotransferase, U/L | 1.026 (1.014–1.039) | <0.0001 | ||
| Total bilirubin, mmol/L | 1.116 (1.061–1.173) | <0.0001 | ||
| Humoral immune parameters | ||||
| IgA, g/L | 1.701 (1.301–2.224) | <0.0001 | 1.201 (0.816–1.770) | 0.353 |
| IgE, IU/mL | 1.001 (0.999–1.002) | 0.279 | ||
| C3, g/L | 0.143 (0.035–0.581) | 0.007 | 0.073 (0.007–0.722) | 0.025 |